main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Brightcove Cards Listing

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Breast Cancer3m 36s

    Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer

    Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
    tumor-infiltrating lymphocytes (tils) promising biomarker
  • Breast Cancer29m 30s

    SABCS Update 2022

    Summary of Key Abstracts from SABCS 2022
    recurrence score tailor-x destiny breast 03 adjuvant cdk4/6 inhibitor antibody drug conjugates
  • Multiple Myeloma4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Prostate Cancer11m 38s

    Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer

    PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
    treatment intensification mhspc triplet therapy peace-1 clinical trial
  • Multiple Myeloma10m 40s

    Recommendations -Management of Myeloma Related Renal Impairment

    Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
    myeloma renal impairment lancet guidelines
  • Oncology1m 36s

    Enhancing Global Access to Cancer Medicines

    Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
    biosimilars access generics
  • Breast Cancer8m 55s

    Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy

    Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
    trastuzumab-deruxtecan (t-dxd) her2 low breast cancers
  • Multiple Myeloma7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Myelodysplastic Syndromes3m 14s

    Low Risk MDS - Key Practice Points

    Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
    ipss -m low risk molecular features
  • Prostate Cancer6m 59s

    Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

    3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
    nmcrpc metastasis free survival spartan prosper & aramis clinical trial
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback